M&A and IB

Healthcare and pharma

Value a drug pipeline the way bankers do, read trial results, model the patent cliff, and know how biotechs, medtech and services earn money.

Read first: Valuation and DCF

7 concepts7 min read25-question test, from a bank of 33Updated

Concept 1 of 71 min

Clinical trials and what they mean for value

The rule
A drug passes Phase I for safety, Phase II for efficacy and dose, and Phase III for efficacy in thousands of patients.
Worked example

A Phase III miss

Given
Value before Phase III600
Patients3,000
Primary endpointmissed
  1. 2 secondary endpoints met: not enough
  2. The programme is likely to stop

The drug's value falls towards zero, taking most of the company with it.

The picture
The gates a drug must pass
  1. Phase ISafety, in a few people
  2. Phase IIEfficacy and dose, in a few hundred
  3. Phase IIIEfficacy, in thousands, on the primary endpoint
  4. ApprovalThe drug can be sold
  5. Phase IVStudies after approval
Why it holds

Phase I tests a few people and Phase II a few hundred. Approval is judged on the pre-specified primary endpoint, and a Phase III failure usually wipes out most of the drug's value.

Phase IV follows approval.

Industry studies put the share of drugs entering Phase I that reach approval near 8% to 10%, lower in oncology. Each step is a gate: a missed primary endpoint, even with secondary endpoints met, rarely supports approval, so the programme usually ends and the risk-adjusted value collapses.

A single-asset biotech can lose most of its value in a day on such news.

Watch out
  • Mixing up the phases: efficacy in large groups is Phase III.
  • Reading met secondary endpoints as enough for approval.
  • Assuming a failed drug keeps its value through other uses.
In the interview
  1. A biotech announces that its Phase III trial missed its primary endpoint. What happens to its valuation, and why?

    A complete answer covers

    • Approval is judged on the pre-specified primary endpoint, so it becomes unlikely.
    • The drug's risk-adjusted value collapses; development usually stops.
    • A single-asset company can lose most of its value in a day.
    • What is left: cash, other pipeline assets, possibly other indications.

Also in our technical interviews, on camera, with a score.

Concept 2 of 71 min

Valuing a pipeline: risk-adjusted NPV

The rule
A drug in development is worth its probability of approval times its value if approved, minus the development costs spent whatever happens.

The why, the charts, the worked example and the interview questions are in Essentials, with every quiz.

See the plansSign in

Concept 3 of 71 min

Patents, exclusivity and generics

The rule
When a small-molecule drug loses exclusivity, generics take most of its sales within a year or two.

The why, the charts, the worked example and the interview questions are in Essentials, with every quiz.

See the plansSign in

Concept 4 of 71 min

Biotech finance: runway, partners and deal terms

The rule
A biotech's runway is its cash divided by its yearly burn, and licensing deals pay it upfront, then milestones, then royalties.

The why, the charts, the worked example and the interview questions are in Essentials, with every quiz.

See the plansSign in

Concept 5 of 71 min

Drug prices and R&D

The rule
Gross-to-net is the gap between a drug's list price and the net price received after rebates, and revenue must be modelled on net prices.

The why, the charts, the worked example and the interview questions are in Essentials, with every quiz.

See the plansSign in

Concept 6 of 71 min

Healthcare services, outsourcing and medtech

The rule
Clinic and care home chains are compared on EV (enterprise value)/EBITDAR (earnings before interest, tax, depreciation, amortisation and rent) because some own their buildings and others lease them.

The why, the charts, the worked example and the interview questions are in Essentials, with every quiz.

See the plansSign in

Concept 7 of 71 min

AdvancedWhy a trial result can triple a biotech's value

The rule
Before a trial result, a drug is worth its chance of success times its value after success, minus the trial's cost.

The why, the charts, the worked example and the interview questions are in Essentials, with every quiz.

See the plansSign in

Recap

  • Phase I tests safety, Phase II efficacy and dose, Phase III efficacy in thousands of patients; only about 1 drug in 10 entering Phase I is approved.
  • Risk-adjusted NPV (net present value) = probability of approval × value if approved − development costs that are certain; probabilities of successive steps multiply.
  • Generics take most of a small molecule's sales within a year or two of patent expiry; biosimilars erode biologics more slowly.
  • Pharma is valued as a sum of the parts: marketed drugs by DCF (discounted cash flow) to their loss of exclusivity, pipeline by risk-adjusted NPV.
  • Biotechs live on runway and partners: upfront, milestones and royalties; contingent value rights bridge disagreements on a pipeline.
Now test it

25 questions on Healthcare and pharma

Timed, like the real one, drawn from a bank of 33. Every answer explained.

Test yourself →